R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Why Scotland is well-positioned to lead in advanced therapie...

The global health burden of complex diseases such as severe lung, liver, and vascular disease is huge, and growing by the second.

R&D

This week in clinical trials: 8th-12th January

In our second clinical trials update of 2024, taking in developments in life sciences research and development from early-stage onwards, we look at a wide range of announcements – from onco

R&D

JP Morgan 2024 – Jeff Smith

Editor-in-chief Jonah Comstock sat down with Jeff Smith, chief research officer at Precision BioSciences, on the side lines of the JP Morgan Healthcare Conference in San Francisco to discus

R&D

Prediction is very difficult, especially if it’s about the f...

In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Carl Hansen, CEO of AbCellera, for a conversation on the discovery and acceleration of antibody therapeutics.

Market Access

Six takeaways from JP Morgan 2024

With another JP Morgan in the rearview mirror, it’s time to take stock of the announcements, the presentations, and, above all, the vibes.

R&D

Nine for 2024, Pt 2: Phase change and the challenges of scal...

In the first segment of Nine for 2024, we examined the continued fragility of healthcare systems, global pharmaceutical market infrastructure, and the journey to greater resilience.